Clinical Trial Update: Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis [Phase 1]

View source ↗

Summary

Phase 1 trial update showing safety and preliminary efficacy data for inhaled OligoG CF-5/20 in cystic fibrosis, sponsored by AlgiPharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• OligoG CF-5/20

Snippet

Sponsor: AlgiPharma AS | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED